Press releases

ObsEva SA Announces that Shareholders Approved all Board Proposals at its 2023 Annual General Meeting held on June 29, 2023

June 30, 2023

Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange

Geneva, Switzerland – June 30, 2023 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women’s health, today announced that shareholders approved all Board proposals at its 2023 Annual General Meeting held on June 29, 2023.

The approved items are as follows:

  • 1. Shareholders approved the Management Report, the Statutory Financial Statements and the Consolidated Financial Statements for Fiscal Year 2022
  • 2. Shareholders granted discharge to the Members of the Board of Directors and to the Executive Committee for year 2022
  • 3. Shareholders approved the proposed appropriation of the Financial Results for year 2022
  • 4. Shareholders approved the proposed elections to the Board of Directors and election of the Chairperson of the Board of Directors
  • 5. Shareholders approved the proposed elections to the Compensation Committee
  • 6. Shareholders approved the re-election of PricewaterhouseCoopers SA as ObsEva SA’s Auditors
  • 7. Shareholders approved the re-election of Perréard de Boccard SA as Independent Representative
  • 8. Shareholders approved the Compensation Report 2022 in a consultative vote and the proposed compensation of the Board of Directors and the Executive Committee
  • 9. Shareholders approved the proposed introduction of a Capital Band and related amendments to the Articles of Association
  • 10. Shareholders approved the proposed increase of ObsEva SA’s Conditional Share Capital for Financing Purposes

For a detailed agenda, including items submitted to shareholders’ vote and related proposals of the Board of Directors, please refer to the full invitation, which may be found in the Investors / General Meetings section of the company’s website www.ObsEva.com

To access the general meetings section of the Company’s website, please click here.

To access the AGM 2023 section of the general meetings section directly, please click here.

To access the full invitation to the AGM 2023 directly, please click here.

About ObsEva

ObsEva is a biopharmaceutical company developing novel therapies to improve women’s reproductive health and pregnancy. ObsEva has established a development program focused on improving in vitro fertilization success rates. ObsEva is listed on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

For further information, please contact:

For general information:

contact@obseva.ch

For investors information:

IR@obseva.ch

ObsEva SA

Chemin des Aulx 12,

1228 Plan-les-Ouates

Switzerland

+41 22 552 1550

###

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue